C3 reports $5.6m first-half loss

CLINICAL Cell Culture Ltd (C3) reported an operating loss of $5.6 million, which was up 9 per cent on the previous result, as it continues its investment in growing its distribution capabilities and supporting sales infrastructure. The figures reflect ongoing product launch activity, which have generated increased revenues of $552,334, up from $116,194 recorded in the previous corresponding period. C3 has been pursuing regulatory approval for its ReCell product in new markets. Overall European market feedback had been encouraging, the company said, with the first European re-order for ReCell placed by C3’s Italian distributor. Other key activities in the half year included the company’s $10 million capital raising in August 2005, the opening of an American regional office in Florida and ReCell being cleared for sale in Argentina, Chile, Israel, New Zealand and South Africa.

Add your comment

BNIQ sponsored byECU School of Business and Law


6th-Australian Institute of Management WA20,000
7th-Murdoch University16,584
8th-South Regional TAFE10,549
9th-Central Regional TAFE10,000
10th-The University of Notre Dame Australia6,708
47 tertiary education & training providers ranked by total number of students in WA

Number of Employees

BNiQ Disclaimer